• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The authors reply.

作者信息

Hotchkiss Richard S, Yende Sachin, Angus Derek C, Moldawer Lyle L, Crouser Elliott, Martin Greg, Coopersmith Craig M, Brakenridge Scott, Mayr Florian B, Park Pauline K

机构信息

Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Surgery, University of Florida College of Medicine, Gainesville, FL Department of Medicine, The Ohio State University School of Medicine, Columbus, OH Department of Medicine, Emory University School of Medicine, Atlanta, GA Department of Surgery, Emory University School of Medicine, Atlanta, GA University of Florida College of Medicine, Gainesville, FL Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI.

出版信息

Crit Care Med. 2019 Sep;47(9):e788-e789. doi: 10.1097/CCM.0000000000003887.

DOI:10.1097/CCM.0000000000003887
PMID:31415323
Abstract
摘要

相似文献

1
The authors reply.作者回复。
Crit Care Med. 2019 Sep;47(9):e788-e789. doi: 10.1097/CCM.0000000000003887.
2
Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity.
Crit Care Med. 2019 Sep;47(9):e788. doi: 10.1097/CCM.0000000000003813.
3
Saved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?
Crit Care Med. 2019 May;47(5):733-735. doi: 10.1097/CCM.0000000000003702.
4
Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.非小细胞肺癌免疫治疗获益的量化——作者回复
Lancet. 2019 Nov 23;394(10212):1904-1905. doi: 10.1016/S0140-6736(19)32605-4.
5
Heather Wakelee on the Role of Checkpoint Inhibitors in Advanced Lung Cancer.希瑟·韦克利谈检查点抑制剂在晚期肺癌中的作用。
Oncology (Williston Park). 2017 Jun 15;31(6):440, 442.
6
Into the Clinic With Nivolumab and Pembrolizumab.走进纳武单抗和帕博利珠单抗的临床应用
Oncologist. 2016 May;21(5):527-8. doi: 10.1634/theoncologist.2016-0099. Epub 2016 Mar 29.
7
Immune checkpoint inhibitors in lung cancer: an update.肺癌中的免疫检查点抑制剂:最新进展
Future Oncol. 2017 May;13(11):955-959. doi: 10.2217/fon-2017-0044.
8
Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.经治非小细胞肺癌患者中PD-1/PD-L1抑制剂(纳武利尤单抗、帕博利珠单抗和阿特珠单抗)的比较:来自贝叶斯网络模型的证据
Int J Cancer. 2018 Dec 1;143(11):3038-3040. doi: 10.1002/ijc.31733. Epub 2018 Sep 25.
9
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?免疫疗法:帕博利珠单抗——癌症的不祥之兆?
Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12.
10
Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.2017年膀胱癌:通过基因组学和免疫检查点阻断推进治疗
Nat Rev Urol. 2018 Feb;15(2):71-72. doi: 10.1038/nrurol.2017.199. Epub 2017 Nov 28.